Drug development for Alzheimer's disease: Where are we now and where are we headed?
- 1 June 2009
- journal article
- review article
- Published by Elsevier in The American Journal of Geriatric Pharmacotherapy
- Vol. 7 (3), 167-185
- https://doi.org/10.1016/j.amjopharm.2009.06.003
Abstract
No abstract availableKeywords
This publication has 91 references indexed in Scilit:
- Ginkgo biloba for Prevention of DementiaA Randomized Controlled TrialJAMA, 2008
- Association of GSK3B With Alzheimer Disease and Frontotemporal DementiaArchives of Neurology, 2008
- Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer DiseaseArchives of Neurology, 2008
- Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT)Archives of Neurology, 2008
- Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tauMolecular Neurodegeneration, 2007
- The Experimental Alzheimer's Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-β Peptide Levels in Cell Culture and MiceJournal of Pharmacology and Experimental Therapeutics, 2006
- β‐Amyloid Degradation and Alzheimer′s DiseaseBioMed Research International, 2006
- RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brainNature Medicine, 2003
- Correlation of nicotinic binding with neurochemical markers in Alzheimer's diseaseJournal of Neural Transmission, 1998
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991